Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor

Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor

US Patent 10898570 · Granted Jan 26, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-HER2 antibodies and immunoconjugates2025
Conjugated chemical inducers of degradation and methods of use2025
PROTAC antibody conjugates and methods of use2023
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhib2023
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhib2022
Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhib2021
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhib2021
Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer2021
Piperidine derivatives as inhibitors of ubiquitin specific protease 72020
Anti-HER2 antibodies and immunoconjugates2020
Immunoconjugates comprising anti-HER2 antibodies and pyrrolobenzodiazepines2019
Anti-HER2 antibodies and immunoconjugates2019